Free tool
FAERS Monitor: Azmiro
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216318 or its brand name (Azmiro, Testosterone Cypionate). Reports on generic versions are filed under their own applications.
Reports
5,970
Serious
2,795
47% of reports
Hospitalization
1,248
Death reported
193
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective437
- product dose omission issue384
- fatigue369
- off label use286
- product deposit273
- pain248
- liquid product physical issue247
- injection site pain240
- poor quality product administered217
- headache199
- myocardial infarction187
- nausea184
- anxiety171
- asthenia164
- diarrhoea160
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 4 |
| 2006 | 5 |
| 2007 | 7 |
| 2008 | 5 |
| 2009 | 21 |
| 2010 | 18 |
| 2011 | 27 |
| 2012 | 39 |
| 2013 | 42 |
| 2014 | 110 |
| 2015 | 283 |
| 2016 | 648 |
| 2017 | 315 |
| 2018 | 423 |
| 2019 | 388 |
| 2020 | 444 |
| 2021 | 378 |
| 2022 | 396 |
| 2023 | 477 |
| 2024 | 580 |
| 2025 | 841 |
| 2026 | 516 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,189 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product depositSignal | 273 | 748.4 | 658.4 | 167,493 |
| liquid product physical issueSignal | 247 | 123.5 | 109.0 | 28,878 |
| poor quality product administeredSignal | 217 | 74.0 | 64.9 | 15,250 |
| product dose omission issueSignal | 384 | 4.6 | 4.2 | 1,094 |
| myocardial infarctionSignal | 187 | 3.8 | 3.3 | 382 |
| injection site painSignal | 240 | 2.8 | 2.4 | 271 |
| anxietySignal | 171 | 2.1 | 1.8 | 101 |
| fatigue | 369 | 1.7 | 1.5 | 102 |
| asthenia | 164 | 1.5 | 1.3 | 31 |
| pain | 248 | 1.4 | 1.3 | 32 |
| drug ineffective | 437 | 1.2 | 1.1 | 11 |
| off label use | 286 | 1.2 | 1.0 | 6 |
| headache | 199 | 1.1 | 1.0 | 2 |
| diarrhoea | 160 | 0.9 | 0.7 | 3 |
| nausea | 184 | 0.8 | 0.7 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.